Dmitry A. Tsekatunov
Dmitry A. Tsekatunov has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Dmitry N. Kushlinskiy
Far Eastern State Medical University; Khabarovsk Territory Regional Clinical Center of Oncology
4 shared publications - Ivan Sokratovich Stilidi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Nikolay Evgenievich Kushlinskii
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Alexei Gratchev
Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Moscow 115478, Russia
3 shared publications - Olga Vladimirovna Kovaleva
N.N. Blokhin National Medical Research Center of Oncology; Kashirskoye shosse, 24, Moscow, 115522, Russian Federation
3 shared publications - Elena Sergeyevna Gershtein
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications
Latest Publications
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 79-84
Assessment methodology of pathomorphological regression of melanoma metastasis in the sentinel lymph node after neoadjuvant/perioperative immunotherapy
This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 79-84
Assessment methodology of pathomorphological regression of melanoma metastasis in the sentinel lymph node after neoadjuvant/perioperative immunotherapy
This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.
- Open Access
- 18 March 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (1) , 1-8
Serum levels of the soluble transmembrane adhesion molecule P-cadherin in healthy women and in patients with malignant and benign ovarian tumors
Background: Cadherins are calcium-dependent transmembrane glycoproteins whose extracellular domains mediate homophilic intercellular interactions. Their soluble forms (s-cadherins), generated through proteolytic cleavage of transmembrane proteins or alternative mRNA splicing, are not anchored in the cell membrane and circulate in the extracellular space or peripheral blood. In the context of carcinogenesis, the role of P-cadherin remains a matter of debate: some studies associate P-cadherin with tumor growth suppression, while others indicate its tumor-promoting properties. Publications on the significance of the soluble P-cadherin in various disorders are scarce. Aim: To perform a comparative analysis of serum sP-cadherin levels in healthy women and in patients with malignant and benign ovarian tumors to assess the clinical significance of the marker. Methods: The retrospective study included 56 patients with epithelial malignant ovarian tumors (median age 57 years), 10 patients with benign ovarian tumors (median age 55 years), and 11 healthy women (median age 56 years) who underwent examination and treatment from 2023 to 2024 in three oncology clinics. Serum levels of sP-cadherin before the initiation of specific treatment were determined with the Human P-Cadherin ELISA Kit (RayBiotech, USA). Results: In the ovarian cancer group, the majority of the patients had the serous type of the tumor (n = 46, 82%), stage III to IV of the disease (n = 45, 80%), T3 and T4 tumors (n = 42, 75%), mostly without regional (N0: n = 41, 73%) and distant metastases (M0: n = 43, 77%). The results of the ROC analysis showed that serum levels of the soluble P-cadherin could not be used as a reliable diagnostic criterion for ovarian malignancies: the area under the curve (AUC) was 0.793 (confidence interval 0.671 to 0.915; p = 0.002). At the optimal cut-off value of 3.01 ng/mL, the test’s sensitivity and specificity were 77% and 73%, respectively. The serum sP-cadherin levels did not show a significant correlation with the key clinical and morphological characteristics of ovarian cancer. Conclusion: Patients with ovarian cancer have an increased serum sP-cadherin level. Further research on this glycoprotein to assess its role in disease outcomes and chemotherapy efficacy is expedient.
- 18 March 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (1) , 1-8
Open AccessSerum levels of the soluble transmembrane adhesion molecule P-cadherin in healthy women and in patients with malignant and benign ovarian tumors
Background: Cadherins are calcium-dependent transmembrane glycoproteins whose extracellular domains mediate homophilic intercellular interactions. Their soluble forms (s-cadherins), generated through proteolytic cleavage of transmembrane proteins or alternative mRNA splicing, are not anchored in the cell membrane and circulate in the extracellular space or peripheral blood. In the context of carcinogenesis, the role of P-cadherin remains a matter of debate: some studies associate P-cadherin with tumor growth suppression, while others indicate its tumor-promoting properties. Publications on the significance of the soluble P-cadherin in various disorders are scarce. Aim: To perform a comparative analysis of serum sP-cadherin levels in healthy women and in patients with malignant and benign ovarian tumors to assess the clinical significance of the marker. Methods: The retrospective study included 56 patients with epithelial malignant ovarian tumors (median age 57 years), 10 patients with benign ovarian tumors (median age 55 years), and 11 healthy women (median age 56 years) who underwent examination and treatment from 2023 to 2024 in three oncology clinics. Serum levels of sP-cadherin before the initiation of specific treatment were determined with the Human P-Cadherin ELISA Kit (RayBiotech, USA). Results: In the ovarian cancer group, the majority of the patients had the serous type of the tumor (n = 46, 82%), stage III to IV of the disease (n = 45, 80%), T3 and T4 tumors (n = 42, 75%), mostly without regional (N0: n = 41, 73%) and distant metastases (M0: n = 43, 77%). The results of the ROC analysis showed that serum levels of the soluble P-cadherin could not be used as a reliable diagnostic criterion for ovarian malignancies: the area under the curve (AUC) was 0.793 (confidence interval 0.671 to 0.915; p = 0.002). At the optimal cut-off value of 3.01 ng/mL, the test’s sensitivity and specificity were 77% and 73%, respectively. The serum sP-cadherin levels did not show a significant correlation with the key clinical and morphological characteristics of ovarian cancer. Conclusion: Patients with ovarian cancer have an increased serum sP-cadherin level. Further research on this glycoprotein to assess its role in disease outcomes and chemotherapy efficacy is expedient.
- 6 March 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- No. 1
Organization and payment for molecular genetic analysis in patients with certain malignancies in the constituent entities of the Russian Federation
Objective. To analyze the system of organization and payment for molecular genetic testing used for diagnosis of six most common malignancies in certain constituent entities of the Russian Federation and to improve its effectiveness. Material and methods. We prepared a list of molecular genetic tests specified in current versions of clinical guidelines for six most common malignancies: cancer of bronchi and lungs (C34), breast cancer (C50), ovarian cancer (C56), prostate cancer (C61), pancreatic cancer (C25), and chronic lymphocytic leukemia (C91.1). Information on scheduled volumes of molecular genetic testing and tariffs was extracted from territorial programs of state guarantees for free care to citizens for 2023-2025, as well as from tariff agreements in compulsory medical insurance system in 8 constituent entities of the Russian Federation (Moscow, Moscow Region, St. Petersburg, Sverdlovsk Region, Novosibirsk Region, Primorsky Krai, Khabarovsk Krai, Amur Region). We surveyed 8 experts from constituent entities of the Russian Federation (managers, heads or employees of diagnostic laboratories, pathology departments) regarding availability of molecular genetic tests for patients with certain malignancies, organization, payment for them and proposals for its improvement. Results. In 8 constituent entities of the Russian Federation, various outpatient molecular genetic tests are performed at the expense of compulsory medical insurance funds in accordance with clinical recommendations. The largest number of tests are performed to diagnose malignant neoplasms of bronchi and lungs, breast cancer and ovarian cancer. The planned number of services established in regions for outpatient molecular genetic tests correspond to federal standards or exceed them. In some regions with well-equipped laboratories with sufficient capacity, molecular genetic tests are performed for other constituent entities of the Russian Federation. The number of such procedures comprises 30-60% of all ones in the region, and payment is made through interterritorial and/or interinstitutional transactions. There is significant interterritorial differentiation in tariffs for the same molecular genetic tests. This may be due to reagents, consumables and equipment. According to experts, higher efficiency of system for organizing and paying for molecular genetic testing in oncology can be associated with federal legislative and organizational initiatives. These are approval of rules for molecular genetic testing, development of a unified methodology for compulsory medical insurance tariffs for outpatient molecular genetic testing at the federal level, approval of new nomenclature of medical services, accelerated registration of reagents and consumables. Another approach is management decisions at the level of regions (increased planned number of outpatient molecular genetic testing, expanding the list of compulsory medical insurance tariffs for molecular genetic testing, annual indexation of tariffs and their compliance with actual expenses incurred). Conclusion. A comprehensive analysis of data from 8 constituent entities of the Russian Federation revealed achievements and certain problems in organizing and paying for molecular genetic testing. The solution of the problems requires some measures to unify approaches to such testing and their pricing at the federal and regional levels.
- 6 March 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- No. 1
Organization and payment for molecular genetic analysis in patients with certain malignancies in the constituent entities of the Russian Federation
Objective. To analyze the system of organization and payment for molecular genetic testing used for diagnosis of six most common malignancies in certain constituent entities of the Russian Federation and to improve its effectiveness. Material and methods. We prepared a list of molecular genetic tests specified in current versions of clinical guidelines for six most common malignancies: cancer of bronchi and lungs (C34), breast cancer (C50), ovarian cancer (C56), prostate cancer (C61), pancreatic cancer (C25), and chronic lymphocytic leukemia (C91.1). Information on scheduled volumes of molecular genetic testing and tariffs was extracted from territorial programs of state guarantees for free care to citizens for 2023-2025, as well as from tariff agreements in compulsory medical insurance system in 8 constituent entities of the Russian Federation (Moscow, Moscow Region, St. Petersburg, Sverdlovsk Region, Novosibirsk Region, Primorsky Krai, Khabarovsk Krai, Amur Region). We surveyed 8 experts from constituent entities of the Russian Federation (managers, heads or employees of diagnostic laboratories, pathology departments) regarding availability of molecular genetic tests for patients with certain malignancies, organization, payment for them and proposals for its improvement. Results. In 8 constituent entities of the Russian Federation, various outpatient molecular genetic tests are performed at the expense of compulsory medical insurance funds in accordance with clinical recommendations. The largest number of tests are performed to diagnose malignant neoplasms of bronchi and lungs, breast cancer and ovarian cancer. The planned number of services established in regions for outpatient molecular genetic tests correspond to federal standards or exceed them. In some regions with well-equipped laboratories with sufficient capacity, molecular genetic tests are performed for other constituent entities of the Russian Federation. The number of such procedures comprises 30-60% of all ones in the region, and payment is made through interterritorial and/or interinstitutional transactions. There is significant interterritorial differentiation in tariffs for the same molecular genetic tests. This may be due to reagents, consumables and equipment. According to experts, higher efficiency of system for organizing and paying for molecular genetic testing in oncology can be associated with federal legislative and organizational initiatives. These are approval of rules for molecular genetic testing, development of a unified methodology for compulsory medical insurance tariffs for outpatient molecular genetic testing at the federal level, approval of new nomenclature of medical services, accelerated registration of reagents and consumables. Another approach is management decisions at the level of regions (increased planned number of outpatient molecular genetic testing, expanding the list of compulsory medical insurance tariffs for molecular genetic testing, annual indexation of tariffs and their compliance with actual expenses incurred). Conclusion. A comprehensive analysis of data from 8 constituent entities of the Russian Federation revealed achievements and certain problems in organizing and paying for molecular genetic testing. The solution of the problems requires some measures to unify approaches to such testing and their pricing at the federal and regional levels.
- Open Access
- 17 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 500
Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications
Background/Objectives: Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have revolutionized cancer immunotherapy, however the clinical relevance of their soluble forms (sPD-1 and sPD-L1) remains less studied. Soluble PD-1 and PD-L1 have been implicated in tumor progression, prognosis, and treatment response across various malignancies. This study aims to provide a comprehensive analysis of sPD-1 and sPD-L1 levels in serum across diverse tumor types, including rare malignancies, and to evaluate their associations with clinicopathological characteristics and prognostic significance. Methods: In this study we analyzed sPD-1 and sPD-L1 levels in serum samples from 675 cancer patients representing a range of malignancies, including ovarian cancer, breast cancer, gastric cancer, colorectal cancer, renal cell carcinoma, and bone tumors. sPD-1 and sPD-L1 concentrations were measured using ELISA. Statistical analyses were performed to evaluate associations between soluble marker concentrations and clinicopathological factors, including tumor stage, size, histological subtype, and survival outcomes. Results: Elevated sPD-L1 levels were observed in several tumor types, including ovarian cancer, renal cell carcinoma, and gastric cancer, where they were associated with features of advanced disease, such as tumor size, stage, and metastases. In contrast, sPD-1 levels showed limited associations, with significant findings solely in gastric cancer and bone tumors, where levels correlated with histological subtype and differentiation. Prognostic analyses identified sPD-L1 as a marker of poor survival outcomes in ovarian cancer and bone tumors, while sPD-1 displayed no consistent prognostic significance. Conclusions: This study identifies the potential of sPD-L1 as a biomarker for tumor progression and prognosis across multiple malignancies. In contrast, sPD-1 showed limited clinical relevance, suggesting the importance of further investigation. These findings contribute to our understanding of soluble immune checkpoint proteins and their integration into personalized oncology strategies.
- 17 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 500
Open AccessAssessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications
Background/Objectives: Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have revolutionized cancer immunotherapy, however the clinical relevance of their soluble forms (sPD-1 and sPD-L1) remains less studied. Soluble PD-1 and PD-L1 have been implicated in tumor progression, prognosis, and treatment response across various malignancies. This study aims to provide a comprehensive analysis of sPD-1 and sPD-L1 levels in serum across diverse tumor types, including rare malignancies, and to evaluate their associations with clinicopathological characteristics and prognostic significance. Methods: In this study we analyzed sPD-1 and sPD-L1 levels in serum samples from 675 cancer patients representing a range of malignancies, including ovarian cancer, breast cancer, gastric cancer, colorectal cancer, renal cell carcinoma, and bone tumors. sPD-1 and sPD-L1 concentrations were measured using ELISA. Statistical analyses were performed to evaluate associations between soluble marker concentrations and clinicopathological factors, including tumor stage, size, histological subtype, and survival outcomes. Results: Elevated sPD-L1 levels were observed in several tumor types, including ovarian cancer, renal cell carcinoma, and gastric cancer, where they were associated with features of advanced disease, such as tumor size, stage, and metastases. In contrast, sPD-1 levels showed limited associations, with significant findings solely in gastric cancer and bone tumors, where levels correlated with histological subtype and differentiation. Prognostic analyses identified sPD-L1 as a marker of poor survival outcomes in ovarian cancer and bone tumors, while sPD-1 displayed no consistent prognostic significance. Conclusions: This study identifies the potential of sPD-L1 as a biomarker for tumor progression and prognosis across multiple malignancies. In contrast, sPD-1 showed limited clinical relevance, suggesting the importance of further investigation. These findings contribute to our understanding of soluble immune checkpoint proteins and their integration into personalized oncology strategies.
- Open Access
- 15 January 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (1) , 67-75
Clinical and laboratory significance of soluble claudin-5 and VEGF in ovarian cancer
Introduction. Claudin 5 is belongs to a family of transmembrane proteins mediating formation of tight junctions between cells, maintenance of cell polarity in epithelial and endothelial layers, regulation of cell membrane permeability, and control of signal transduction inside the cells. Results of a small number of studies show that vascular endothelial growth factor (VEGF) also affects formation of tight junctions, in particular through regulation of claudin 5 expression. In addition to their physiological functions, claudin 5 and VEGF play an important role in pathogenesis of various diseases including malignant neoplasms.Aim. To study the levels of claudin 5 and VEGF in serum of patients with ovarian cancer and evaluate their clinical significance.Materials and methods. In total, 123 patients with ovarian cancer (median age 54 years) and 32 control group healthy women (median age 54 years) were examined. Claudin 5 and VEGF levels in serum were measured prior to treatment using Human CLDN5 (Claudin 5) ELISA Kit (Elabscience, China) and Human VEGF Immunoassay (Quantikine®, RD Systems, uSA) in accordance with the manufacturer’s instructions. Statistical analysis of the obtained data was performed using the GraphPad Prizm v. 10 software. The values were compared and their correlations quantified using nonparametric Mann–Whitney, Kruskal–Wallis tests and Spearman’s rank correlation coefficient. Overall survival was analyzed using the Kaplan–Meier method.Results. Claudin 5 was found in serum of 97 % of patients with ovarian cancer and 94 % of the control group women. Median (1st quartile (Q1) – 3rd quartile (Q3)) level of claudin 5 in serum of healthy women was 0.77 (0.48–1.17) ng/mL, patients with ovarian cancer – 0.95 (0.43–1.77) mg/mL. ROC analysis of informational value of claudin 5 in ovarian cancer showed unsatisfactory diagnostic accuracy of the model (area under the ROC curve (AuC) 0.613 (95 % confidence interval (CI) 0.513–0.713); p = 0.049): for median threshold value of 0.95 ng/mL the assay had sensitivity of 50 % and specificity of 60 %. VEGF was found in all patients with ovarian cancer and healthy women; median (Q1–Q3) VEGF level in serum of healthy women was 45.6 (13.3–89.09) pg/mL and was statistically significantly lower than in patients with ovarian cancer: 274.7 ng/mL (199.0–472.5). ROC analysis for ovarian cancer showed good diagnostic accuracy of the model (AuC 0.942 (95 % CI 0.886–0.997); p 0.0001) which allows to use serum VEGF level as a diagnostic criterion. The best results for sensitivity and specificity (71 and 100 %, respectively) were obtained at VEGF threshold level of 226.2 pg/mL. Serum claudin 5 and VEGF levels are associated with ovarian cancer progression. However, claudin 5 and VEGF are not statistically significant prognostic markers for this disease.Conclusion. Serum levels of VEGF and claudin 5 in patients with ovarian cancer are significantly higher than in control group women and positively correlate with each other. Additionally, VEGF has relatively good diagnostic characteristics compared to healthy women of the control group. VEGF and claudin 5 levels are associated with the presence of distant metastases which points at their potential role in tumor progression. However, at this research stage, these markers cannot be recommended as diagnostic or prognostic criteria in ovarian cancer and require further study.
- 15 January 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (1) , 67-75
Open AccessClinical and laboratory significance of soluble claudin-5 and VEGF in ovarian cancer
Introduction. Claudin 5 is belongs to a family of transmembrane proteins mediating formation of tight junctions between cells, maintenance of cell polarity in epithelial and endothelial layers, regulation of cell membrane permeability, and control of signal transduction inside the cells. Results of a small number of studies show that vascular endothelial growth factor (VEGF) also affects formation of tight junctions, in particular through regulation of claudin 5 expression. In addition to their physiological functions, claudin 5 and VEGF play an important role in pathogenesis of various diseases including malignant neoplasms.Aim. To study the levels of claudin 5 and VEGF in serum of patients with ovarian cancer and evaluate their clinical significance.Materials and methods. In total, 123 patients with ovarian cancer (median age 54 years) and 32 control group healthy women (median age 54 years) were examined. Claudin 5 and VEGF levels in serum were measured prior to treatment using Human CLDN5 (Claudin 5) ELISA Kit (Elabscience, China) and Human VEGF Immunoassay (Quantikine®, RD Systems, uSA) in accordance with the manufacturer’s instructions. Statistical analysis of the obtained data was performed using the GraphPad Prizm v. 10 software. The values were compared and their correlations quantified using nonparametric Mann–Whitney, Kruskal–Wallis tests and Spearman’s rank correlation coefficient. Overall survival was analyzed using the Kaplan–Meier method.Results. Claudin 5 was found in serum of 97 % of patients with ovarian cancer and 94 % of the control group women. Median (1st quartile (Q1) – 3rd quartile (Q3)) level of claudin 5 in serum of healthy women was 0.77 (0.48–1.17) ng/mL, patients with ovarian cancer – 0.95 (0.43–1.77) mg/mL. ROC analysis of informational value of claudin 5 in ovarian cancer showed unsatisfactory diagnostic accuracy of the model (area under the ROC curve (AuC) 0.613 (95 % confidence interval (CI) 0.513–0.713); p = 0.049): for median threshold value of 0.95 ng/mL the assay had sensitivity of 50 % and specificity of 60 %. VEGF was found in all patients with ovarian cancer and healthy women; median (Q1–Q3) VEGF level in serum of healthy women was 45.6 (13.3–89.09) pg/mL and was statistically significantly lower than in patients with ovarian cancer: 274.7 ng/mL (199.0–472.5). ROC analysis for ovarian cancer showed good diagnostic accuracy of the model (AuC 0.942 (95 % CI 0.886–0.997); p 0.0001) which allows to use serum VEGF level as a diagnostic criterion. The best results for sensitivity and specificity (71 and 100 %, respectively) were obtained at VEGF threshold level of 226.2 pg/mL. Serum claudin 5 and VEGF levels are associated with ovarian cancer progression. However, claudin 5 and VEGF are not statistically significant prognostic markers for this disease.Conclusion. Serum levels of VEGF and claudin 5 in patients with ovarian cancer are significantly higher than in control group women and positively correlate with each other. Additionally, VEGF has relatively good diagnostic characteristics compared to healthy women of the control group. VEGF and claudin 5 levels are associated with the presence of distant metastases which points at their potential role in tumor progression. However, at this research stage, these markers cannot be recommended as diagnostic or prognostic criteria in ovarian cancer and require further study.
- Open Access
- 10 September 2024
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 52 (3) , 149-161
The group of hypermethylated long noncoding RNA genes is associated with different types of metastasis in ovarian cancer
Background: Ovarian tumors are characterized by asymptomatic progression until their late stages, when at the time of diagnosis the patient already has extensive metastatic disease. In addition to lymphogenous and hematogenous metastasis in ovarian cancer, there are peritoneal dissemination and metastasis to the greater omentum with ascites; moreover, peritoneal carcinomatosis is the predominant route of metastasizing of ovarian cancer. Epigenetic factors, such as gene methylation, regulatory microRNAs and long non-coding RNAs (lncRNAs), contribute to progression of this cancer. Our previous bioinformatic and experimental studies have identified 13 genes of lncRNAs (GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, PLUT/PDX1-AS1, SNHG1, SNHG6, SNHG12, SNHG17, TINCR, TP53TG1, TUG1) hypermethylated in the ovarian neoplasms. Aim: To evaluate the clinical significance of methylation levels of 13 lncRNA genes (GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, PLUT/PDX1-AS1, SNHG1, SNHG6, SNHG12, SNHG17, TINCR, TP53TG1, TUG1) associated with various types of ovarian cancer metastasis, including lymphogenous, peritoneal, omental, and distant metastases. Methods: The methylation levels of lncRNA genes GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, PLUT/PDX1-AS1, SNHG1, SNHG6, SNHG12, SNHG17, TINCR, TP53TG1, TUG1 were analyzed by quantitative real-time methylation-specific polymerase chain reaction. We tested 122 duplicate samples of ovarian neoplasms, including 104 malignancies and 18 borderline tumors, as well as 45 peritoneal macro metastases, collected in the N.N. Blokhin National Medical Research Center of Oncology in 2020 to 2023. The study included 21 samples of primary tumor from patients with lymphogenous metastases, 45 samples from patients with peritoneal dissemination, 61 from those with omental metastases, 49 from patients with ascites, and 9 with distant metastases. Results: The tumor samples from the patients with lymphatic nodes metastases showed a significant increase in the methylation level of two lncRNA genes: SNHG6 (p = 0.044) and SNHG12 (p = 0.006). Peritoneal dissemination was associated with hypermethylation of four lncRNA genes: GAS5, HOTAIR, LINC00472 (p 0.05), and most significantly TINCR (p = 0.001). GAS5, HOTAIR, LINC00886 (p 0.05) and most significantly LINC00472 (p 0.001) hypermethylation was typical for omental metastasis, and that of LINC00472 and LINC00886, with ascites (p 0.05). Peritoneal macroscopic metastases demonstrated increased methylation of MAFG-DT (p 0.001) and TP53TG1 (p 0.001) and desmethylation of LINC00886 (p = 0.003) and SNHG12 (p = 0.002), compared to their primary tumors. Conclusion: We performed the analysis of clinical significance of 13 hypermethylated lncRNA genes in ovarian cancer and were the first to show that 10 genes (GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, SNHG6, SNHG12, TINCR, TP53TG1, TUG1) were associated with various types of ovarian tumor metastasis. Also, we were able to determine certain panels of lncRNA, which, if demonstrate abnormal methylation, were specific for lymphogenous and peritoneal metastasis of ovarian tumors.
- 10 September 2024
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 52 (3) , 149-161
Open AccessThe group of hypermethylated long noncoding RNA genes is associated with different types of metastasis in ovarian cancer
Background: Ovarian tumors are characterized by asymptomatic progression until their late stages, when at the time of diagnosis the patient already has extensive metastatic disease. In addition to lymphogenous and hematogenous metastasis in ovarian cancer, there are peritoneal dissemination and metastasis to the greater omentum with ascites; moreover, peritoneal carcinomatosis is the predominant route of metastasizing of ovarian cancer. Epigenetic factors, such as gene methylation, regulatory microRNAs and long non-coding RNAs (lncRNAs), contribute to progression of this cancer. Our previous bioinformatic and experimental studies have identified 13 genes of lncRNAs (GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, PLUT/PDX1-AS1, SNHG1, SNHG6, SNHG12, SNHG17, TINCR, TP53TG1, TUG1) hypermethylated in the ovarian neoplasms. Aim: To evaluate the clinical significance of methylation levels of 13 lncRNA genes (GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, PLUT/PDX1-AS1, SNHG1, SNHG6, SNHG12, SNHG17, TINCR, TP53TG1, TUG1) associated with various types of ovarian cancer metastasis, including lymphogenous, peritoneal, omental, and distant metastases. Methods: The methylation levels of lncRNA genes GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, PLUT/PDX1-AS1, SNHG1, SNHG6, SNHG12, SNHG17, TINCR, TP53TG1, TUG1 were analyzed by quantitative real-time methylation-specific polymerase chain reaction. We tested 122 duplicate samples of ovarian neoplasms, including 104 malignancies and 18 borderline tumors, as well as 45 peritoneal macro metastases, collected in the N.N. Blokhin National Medical Research Center of Oncology in 2020 to 2023. The study included 21 samples of primary tumor from patients with lymphogenous metastases, 45 samples from patients with peritoneal dissemination, 61 from those with omental metastases, 49 from patients with ascites, and 9 with distant metastases. Results: The tumor samples from the patients with lymphatic nodes metastases showed a significant increase in the methylation level of two lncRNA genes: SNHG6 (p = 0.044) and SNHG12 (p = 0.006). Peritoneal dissemination was associated with hypermethylation of four lncRNA genes: GAS5, HOTAIR, LINC00472 (p 0.05), and most significantly TINCR (p = 0.001). GAS5, HOTAIR, LINC00886 (p 0.05) and most significantly LINC00472 (p 0.001) hypermethylation was typical for omental metastasis, and that of LINC00472 and LINC00886, with ascites (p 0.05). Peritoneal macroscopic metastases demonstrated increased methylation of MAFG-DT (p 0.001) and TP53TG1 (p 0.001) and desmethylation of LINC00886 (p = 0.003) and SNHG12 (p = 0.002), compared to their primary tumors. Conclusion: We performed the analysis of clinical significance of 13 hypermethylated lncRNA genes in ovarian cancer and were the first to show that 10 genes (GAS5, HOTAIR, LINC00472, LINC00886, MAFG-DT, SNHG6, SNHG12, TINCR, TP53TG1, TUG1) were associated with various types of ovarian tumor metastasis. Also, we were able to determine certain panels of lncRNA, which, if demonstrate abnormal methylation, were specific for lymphogenous and peritoneal metastasis of ovarian tumors.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (2)
Clinical and prognostic significance of sPD-1 and sPD-L1 in ovarian cancer
Клиническая и прогностическая значимость sPD-1 и sPD-L1 при раке яичников
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (2)
Open AccessClinical and prognostic significance of sPD-1 and sPD-L1 in ovarian cancer
Клиническая и прогностическая значимость sPD-1 и sPD-L1 при раке яичников